Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BLL006
MIFTS: 65

Bullous Pemphigoid

Categories: Immune diseases, Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bullous Pemphigoid

About this section

MalaCards integrated aliases for Bullous Pemphigoid:

Name: Bullous Pemphigoid 12 77 54 60 15 17 74
Senile Dermatitis Herpetiformis 54 74
Benign Pemphigus 54 74
Pemphigoid 54 38
Pemphigoid, Bullous 45
Pemphigoid Bullous 56
Old Age Pemphigus 54
Parapemphigus 54

Characteristics:

Orphanet epidemiological data:

60
bullous pemphigoid
Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Skin diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 34 35
Orphanet: 60  
Rare skin diseases


External Ids:

Disease Ontology 12 DOID:8506
KEGG 38 H01650
ICD9CM 36 694.5
MeSH 45 D010391
SNOMED-CT 69 77090002 86142006
ICD10 34 L12 L12.0 L12.9
MESH via Orphanet 46 D010391
ICD10 via Orphanet 35 L12.0
UMLS via Orphanet 75 C0030805
Orphanet 60 ORPHA703
Sources

Summaries for Bullous Pemphigoid

About this section
NIH Rare Diseases : 54 Bullous pemphigoid is a skin disorder characterized by large blisters. The blisters are usually located on the arms, legs, or middle of the body. In some people, the mouth or genitals are also affected. The blisters may break open and form ulcers or open sores. Bullous pemphigoid usually occurs in older persons and is rare in young people. Symptoms may come and go. In most patients, the condition goes away after several years. Bullous pemphigoid is an autoimmune disorder which occurs when the body's immune system attacks and destroys healthy body tissue by mistake. Treatment may include corticosteroids taken by mouth or applied to the skin. Medicines that suppress the immune system may also be prescribed. For some, antibiotics in the tetracycline family are useful.

MalaCards based summary : Bullous Pemphigoid, also known as senile dermatitis herpetiformis, is related to lichen planus pemphigoides and lichen planus. An important gene associated with Bullous Pemphigoid is COL17A1 (Collagen Type XVII Alpha 1 Chain), and among its related pathways/superpathways are ERK Signaling and Integrin Pathway. The drugs Prednisone and Clobetasol have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and eye, and related phenotypes are diabetes mellitus and abnormal blistering of the skin

Disease Ontology : 12 An autoimmune disease of skin and connective tissue characterized by large blisters.

Wikipedia : 77 Bullous pemphigoid is an autoimmune pruritic skin disease preferentially in elderly people, that may... more...

Sources

Related Diseases for Bullous Pemphigoid

About this section

Diseases related to Bullous Pemphigoid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 402)
# Related Disease Score Top Affiliating Genes
1 lichen planus pemphigoides 33.1 COL17A1 DST ITGB4
2 lichen planus 31.1 COL17A1 DSG3 DST
3 epidermolysis bullosa acquisita 31.0 COL17A1 DST ITGB4 LAMA3
4 linear iga disease 30.9 COL17A1 DST ITGB4
5 dermatitis 30.7 CCL11 CCL17 DSG1 IL5
6 lichen sclerosus 30.6 COL17A1 HLA-DQB1 HLA-DRB1
7 pemphigus 30.6 COL17A1 DSG1 DSG3 DSP DST EVPL
8 cicatricial pemphigoid 30.6 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMC2
9 conjunctivitis 30.5 CCL11 IL5 RNASE3
10 pemphigoid gestationis 30.5 CCL11 COL17A1 DST HLA-DRB1 IL5
11 esophagitis 30.4 CCL11 DSG1 IL5
12 herpetiform pemphigus 30.4 DSG1 DSG3 DST
13 epidermolysis bullosa simplex 30.3 COL17A1 DST ITGB4 PLEC
14 gastroenteritis 30.3 CCL11 IL5 RNASE3
15 chronic eosinophilic pneumonia 30.3 CCL11 IL5 RNASE3
16 autoimmune disease 30.3 COL17A1 DSG1 HLA-DQB1 HLA-DRB1 TNFSF13B
17 ocular cicatricial pemphigoid 30.3 HLA-DQB1 HLA-DRB1 ITGA6 ITGB4 RNASE3
18 hypereosinophilic syndrome 30.1 CCL11 CCL17 IL5 RNASE3
19 pemphigus foliaceus 30.0 DSG1 DSG3 DST EVPL HLA-DRB1 PPL
20 chronic conjunctivitis 29.9 CCL11 IL5 RNASE3
21 pemphigus vulgaris 29.9 DSG1 DSG3 DSP DST EVPL HLA-DRB1
22 epidermolysis bullosa 29.9 COL17A1 DSP DST ITGA6 ITGB4 LAMA3
23 bronchiolitis 29.8 CCL11 IL5 RNASE3
24 dermatitis, atopic 29.8 CCL11 CCL17 IL5 RNASE3
25 churg-strauss syndrome 29.8 CCL17 IL5 RNASE3
26 pemphigus vegetans 29.7 DSG1 PPL
27 junctional epidermolysis bullosa 29.7 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3
28 eosinophilic pneumonia 29.6 CCL11 CCL17 IL5 RNASE3
29 epidermolysis bullosa, junctional, non-herlitz type 29.6 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3
30 atopic keratoconjunctivitis 29.4 IL5 RNASE3
31 keratoconjunctivitis 29.2 CCL11 CCL17 IL5 RNASE3
32 paraneoplastic pemphigus 28.9 COL17A1 DSG1 DSG3 DSP DST EVPL
33 subcorneal pustular dermatosis 28.7 CCL17 COL17A1 DSG1 DSG3 DST EVPL
34 cellulitis 28.5 COL17A1 DSG1 DSG3 DSP DST IL5
35 skin disease 27.2 CCL11 CCL17 COL17A1 DSG1 DSG3 DSP
36 brunsting-perry syndrome 12.1
37 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 11.3
38 autoimmune disease, multisystem, infantile-onset, 2 11.3
39 recessive dystrophic epidermolysis bullosa-generalized other 11.3
40 pseudomembranous conjunctivitis 11.0
41 psoriasis 10.7
42 pemphigus vulgaris, familial 10.7
43 dermatitis herpetiformis, familial 10.7
44 dermatitis herpetiformis 10.7
45 lupus erythematosus 10.5
46 melanoma 10.5
47 scabies 10.5
48 multiple sclerosis 10.4
49 diabetes mellitus 10.4
50 systemic lupus erythematosus 10.4

Comorbidity relations with Bullous Pemphigoid via Phenotypic Disease Network (PDN):


Acute Cystitis Decubitus Ulcer
Deficiency Anemia Heart Disease
Pemphigus Protein-Energy Malnutrition
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Bullous Pemphigoid:



Diseases related to Bullous Pemphigoid
Sources

Symptoms & Phenotypes for Bullous Pemphigoid

About this section

Human phenotypes related to Bullous Pemphigoid:

60 33 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 diabetes mellitus 60 33 hallmark (90%) Very frequent (99-80%) HP:0000819
2 abnormal blistering of the skin 60 33 hallmark (90%) Very frequent (99-80%) HP:0008066
3 weight loss 60 33 hallmark (90%) Very frequent (99-80%) HP:0001824
4 autoimmunity 60 33 hallmark (90%) Very frequent (99-80%) HP:0002960
5 recurrent infections 60 33 hallmark (90%) Very frequent (99-80%) HP:0002719
6 erythema 60 33 hallmark (90%) Very frequent (99-80%) HP:0010783
7 macule 60 33 hallmark (90%) Very frequent (99-80%) HP:0012733
8 eczema 60 33 hallmark (90%) Very frequent (99-80%) HP:0000964
9 urticaria 60 33 hallmark (90%) Very frequent (99-80%) HP:0001025
10 psoriasiform dermatitis 60 33 frequent (33%) Frequent (79-30%) HP:0003765

GenomeRNAi Phenotypes related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 CCL11 CCL17 COL17A1 DSG1 DSG3 DSP

MGI Mouse Phenotypes related to Bullous Pemphigoid:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10 DSG1 DSG3 DSP HLA-DQB1 IL5 ITGA6
2 digestive/alimentary MP:0005381 9.97 DSG3 DSP HLA-DQB1 IL5 ITGA6 ITGB4
3 craniofacial MP:0005382 9.91 DSG3 DSP ITGA6 ITGB4 LAMA3 LAMB3
4 immune system MP:0005387 9.9 CCL11 CCL17 DSG3 HLA-DQB1 IL5 ITGA6
5 integument MP:0010771 9.65 DSG1 DSG3 DSP EVPL ITGA6 ITGB4
6 respiratory system MP:0005388 9.28 CCL11 DSG3 HLA-DQB1 IL5 ITGA6 ITGB4
Sources

Drugs & Therapeutics for Bullous Pemphigoid

About this section

Drugs for Bullous Pemphigoid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Clobetasol Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2 25122-46-7, 25122-41-2 32798 5311051
3
Omalizumab Approved, Investigational Phase 4 242138-07-4
4 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
5 Hormones Phase 4,Phase 3,Phase 2
6 Antineoplastic Agents, Hormonal Phase 4
7 Hormone Antagonists Phase 4,Phase 3,Phase 2
8 glucocorticoids Phase 4,Phase 3,Phase 2
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
10 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
11 Anti-Allergic Agents Phase 4
12 Immunoglobulin E Phase 4
13 Anti-Asthmatic Agents Phase 4
14 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
15 Respiratory System Agents Phase 4
16
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
17
leucovorin Approved Phase 3 58-05-9 6006 143
18
rituximab Approved Phase 3,Phase 1,Phase 2 174722-31-7 10201696
19
Mycophenolic acid Approved Phase 3,Phase 2 24280-93-1 446541
20
Cyclophosphamide Approved, Investigational Phase 3 6055-19-2, 50-18-0 2907
21
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
22 Antimetabolites Phase 3,Phase 2,Phase 1
23 Vitamin B Complex Phase 3,Phase 1,Phase 2
24 Immunosuppressive Agents Phase 3,Phase 2
25 Antimetabolites, Antineoplastic Phase 3,Phase 2
26 Immunologic Factors Phase 3,Phase 2,Phase 1
27 Nucleic Acid Synthesis Inhibitors Phase 3
28 Folate Phase 3,Phase 1,Phase 2
29 Vitamin B9 Phase 3,Phase 1,Phase 2
30 Antirheumatic Agents Phase 3,Phase 2,Phase 1
31 Folic Acid Antagonists Phase 3
32 Dermatologic Agents Phase 3,Phase 1,Phase 2,Not Applicable
33 Anti-Bacterial Agents Phase 3,Phase 2
34 Anti-Infective Agents Phase 3,Phase 2
35 Antineoplastic Agents, Immunological Phase 3,Phase 1,Phase 2
36 gamma-Globulins Phase 3,Phase 2,Phase 1
37 Immunoglobulins, Intravenous Phase 3,Phase 2,Phase 1
38 Rho(D) Immune Globulin Phase 3,Phase 2,Phase 1
39 Antibiotics, Antitubercular Phase 3,Phase 2
40 Antitubercular Agents Phase 3,Phase 2
41 Antineoplastic Agents, Alkylating Phase 3
42 Alkylating Agents Phase 3
43
Leflunomide Approved, Investigational Phase 2 75706-12-6 3899
44
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
45
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
46
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
47
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
48
Azathioprine Approved Phase 2 446-86-6 2265
49 Ixekizumab Approved, Investigational Phase 2 1143503-69-8
50
Infliximab Approved Phase 1, Phase 2 170277-31-3

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Omalizumab in Bullous Pemphigoid Completed NCT00472030 Phase 4 Omalizumab;prednisone
2 Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid Recruiting NCT02360202 Phase 4 Clobetasol Propionate cream treatment
3 Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid Unknown status NCT02313870 Phase 3 clobetasol propionate + Methotrexate;clobetasol propionate alone
4 Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid Completed NCT00525616 Phase 3 Mabthera
5 Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids Completed NCT01408550 Phase 3 NPB-01;Placebo
6 Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid. Recruiting NCT02993133 Phase 3 Cellcept® in autoimmune bullous dermatoses
7 Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid Not yet recruiting NCT03295383 Phase 3 Rituximab 1g IV;Cyclophosphamide 50Mg Oral Tablet;Placebo of Rituximab;Placebo Oral Tablet
8 Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid Unknown status NCT00802243 Phase 2 leflunomide
9 Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids. Completed NCT00809822 Phase 2 NPB-01;Placebo
10 Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid Completed NCT00431119 Phase 2 Azathioprine or Mycophenolate mofetil
11 Rituximab in the Treatment of Patients With Bullous Pemphigoid Completed NCT00286325 Phase 1, Phase 2 Rituximab
12 Anti-IL-5 Therapy in Bullous Pemphigoid (BP) Completed NCT01705795 Phase 2 Mepolizumab (a-IL-5 antibody);Placebo
13 Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid Completed NCT02226146 Phase 2
14 Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid Completed NCT00584935 Phase 1, Phase 2 Rituximab
15 Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
16 Ixekizumab in the Treatment of Bullous Pemphigoid Recruiting NCT03099538 Phase 2 Ixekizumab
17 A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid Recruiting NCT03286582 Phase 2 AC-203 1% Topical Ointment;Clobetasol 0.05% Topical Ointment
18 Limbal Epithelial Stem Cell Transplantation: a Phase II Multicenter Trial Recruiting NCT02318485 Phase 2
19 Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment Terminated NCT01688882 Phase 2 QGE031;Placebo
20 Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid Terminated NCT01571895 Phase 2 DF2156A
21 Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Withdrawn NCT02126020 Phase 1, Phase 2 topical infliximab
22 The Improvement of Limbal Epithelial Culture Technique by Using Collagenase to Isolate Limbal Stem Cells Unknown status NCT02202642 Phase 1
23 Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies Completed NCT00691210 Phase 1 Vorinostat;Niacinamide;Etoposide
24 Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders Recruiting NCT02502903 Phase 1 BIV009
25 Topical Infliximab for Sterile Corneal Melt Recruiting NCT02987686 Phase 1 Topical Infliximab
26 Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions Withdrawn NCT02042027 Phase 1 Gamunex-C
27 Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid Unknown status NCT02874079 Not Applicable
28 Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid Unknown status NCT02837965 treatment with topical superpotent corticosteroid therapy;treatment with systemic therapy (methotrexate);treatment systemic therapy (prednisone);treatment with systemic therapy (prednisone);treatment with systemic therapy (doxycycline)
29 Explore the Mechanisms of Pruritus in Bullous Pemphigoid Patients During Remission Unknown status NCT01265082
30 Wound Dressings for Pemphigus and Pemphigoid Unknown status NCT02365675 Not Applicable
31 Autoimmune Blistering Diseases Study Unknown status NCT02753777
32 Serum FFA Desaturase Activity Index in Patients on High Dose Corticosteroids Unknown status NCT02872584 Prednisone
33 Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid Completed NCT02883894
34 Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid Completed NCT03272958
35 Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients Completed NCT03320798
36 Pruritus and Pemphigoid in Nursing Home Patients Completed NCT02823067
37 Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus Completed NCT00213421 Dermoval
38 Register of Autoimmune Bullous Dermatoses Completed NCT02899923
39 Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study Completed NCT00116090
40 A Study of the Association of Sleep Dysfunction and Burning Mouth Syndrome Completed NCT00862576
41 Immune Responses to Antigens in Non-infectious Eye Inflammatory Diseases Completed NCT00357071
42 Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid? Recruiting NCT03636763 data report
43 Cytokines in Blister Fluids of Bullous Pemphigoid (BP) Recruiting NCT03856840
44 Prevalence of Cutaneous Autoimmune Phenomena in HIV Infected Patients Recruiting NCT03129308
45 Identification of Vulnerability Factors in the Course of Pemphigus Patients Recruiting NCT02237313 Not Applicable
46 Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis Recruiting NCT03839069 Not Applicable
47 Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation Available NCT02149732
48 Trichoscopy in Diagnosis of Immunobollous Diseases Not yet recruiting NCT03478072
49 Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid Terminated NCT01559155
50 Implantable Intraocular Pressure Sensor for Glaucoma Monitoring in Patients With Boston Keratoprosthesis Type 1 Withdrawn NCT03421548 Not Applicable

Search NIH Clinical Center for Bullous Pemphigoid

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: pemphigoid, bullous

Sources

Genetic Tests for Bullous Pemphigoid

About this section
Sources

Anatomical Context for Bullous Pemphigoid

About this section

MalaCards organs/tissues related to Bullous Pemphigoid:

42
Skin, T Cells, Eye, Neutrophil, Testes, Breast, B Cells
Sources

Publications for Bullous Pemphigoid

About this section

Articles related to Bullous Pemphigoid:

(show top 50) (show all 2170)
# Title Authors Year
1
Acquired hemophilia A associated with bullous pemphigoid and multiple myeloma: a case report. ( 30882350 )
2019
2
BP180 Autoantibodies Target Different Epitopes in Multiple Sclerosis or Alzheimer's Disease than in Bullous Pemphigoid. ( 30315782 )
2019
3
IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid. ( 30557620 )
2019
4
Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes. ( 30624566 )
2019
5
Assessment of the Prevalence of Mucosal Involvement in Bullous Pemphigoid. ( 30624571 )
2019
6
Secukinumab decreased circulating anti-BP180-NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid. ( 30628103 )
2019
7
Bullous pemphigoid associated with linagliptin treatment in diabetic patients with chronic kidney disease. ( 30630688 )
2019
8
Actigraphy-measured nocturnal wrist movements and assessment of sleep quality in patients with bullous pemphigoid: a pilot case-control study. ( 30652344 )
2019
9
Omalizumab as an alternative therapeutic tool in the treatment of Bullous Pemphigoid: a case report. ( 30659716 )
2019
10
Neurological Disorders are Associated with Bullous Pemphigoid. ( 30663128 )
2019
11
Epitope spreading phenomena in dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. ( 30675718 )
2019
12
Bullous Pemphigoid Presenting as Oropharyngeal Hemorrhage. ( 30676623 )
2019
13
Pemphigoid nodularis - rare presentation of bullous pemphigoid: A case report and literature review. ( 30679985 )
2019
14
Bullous Pemphigoid Associated With a New Combination Checkpoint Inhibitor Immunotherapy ( 30681807 )
2019
15
Methotrexate is safe and efficient as long-term treatment for bullous pemphigoid. ( 30734720 )
2019
16
Reply to: Comment on "Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case control study" and a case report of glucagon-like peptide-1 receptor agonist induced bullous pemphigoid. ( 30738121 )
2019
17
"Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study". ( 30738123 )
2019
18
Severe bullous pemphigoid in a metastatic lung cancer patient treated with pembrolizumab. ( 30758879 )
2019
19
Localized vulvar bullous pemphigoid of childhood: A rare cause of persistent vulvar erosions in children. ( 30762244 )
2019
20
Biochip detection of BP180 autoantibodies in blister fluid for the serodiagnosis of bullous pemphigoid: A pilot study. ( 30762788 )
2019
21
Drugs used for neurological and psychiatric conditions increase the risk of bullous pemphigoid: a case-control study. ( 30771421 )
2019
22
Bullous Pemphigoid with Atypical Skin Lesions and Acute Interstitial Nephritis: A Case Report and Focused Literature Review. ( 30773528 )
2019
23
The association between neurological diseases, malignancies and cardiovascular comorbidities among patients with bullous pemphigoid: Case-control study in a specialized Polish center. ( 30784240 )
2019
24
Bullous Pemphigoid IgG Induces Cell Dysfunction and Enhances the Motility of Epidermal Keratinocytes via Rac1/Proteasome Activation. ( 30809225 )
2019
25
Bullous pemphigoid and cancer in Taiwan. ( 30821366 )
2019
26
Dramatic exacerbation of bullous pemphigoid following rituximab and successful treatment with omalizumab. ( 30827944 )
2019
27
B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid. ( 30837635 )
2019
28
Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. ( 30844553 )
2019
29
Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid. ( 30848289 )
2019
30
Exacerbation of well-controlled bullous pemphigoid by the administration of a dipeptidyl peptidase-4 inhibitor: a case report. ( 30859617 )
2019
31
Presence of anti-BP180 and anti-BP230 in the CSF of patients with bullous pemphigoid and neurologic disease: is there any intrathecal synthesis? ( 30883687 )
2019
32
Bullous pemphigoid: more than one disease? ( 30891848 )
2019
33
Gliptin-Associated Bullous Pemphigoid: A Valuable Model of the Mechanism of Breakdown of Immune Tolerance against BP180. ( 30904079 )
2019
34
Bullous erythroderma: novel association of pityriasis rubra pilaris with bullous pemphigoid. ( 30129048 )
2019
35
Cutaneous Mucormycosis Following a Bullous Pemphigoid Flare in a Chronic Lymphocytic Leukemia Patient on Ibrutinib. ( 29760835 )
2018
36
HLA-C*17, DQB1*03:01, DQA1*01:03 and DQA1*05:05 Alleles Associated to Bullous Pemphigoid in Brazilian Population. ( 29386826 )
2018
37
Mortality and Comorbidity Profiles of Patients with Bullous Pemphigoid in Korea. ( 29386827 )
2018
38
A case of bullous pemphigoid with IgG antibodies against LAD-1, but not BP180 NC16a domain or BP230. ( 29378676 )
2018
39
Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in a patient with acquired reactive perforating collagenosis. ( 29446164 )
2018
40
Regulatory T-cell deficiency leads to pathogenic bullous pemphigoid antigen 230 autoantibody and autoimmune bullous disease. ( 29704595 )
2018
41
Circulating anti-bullous pemphigoid 180 autoantibody can be detected in a wide clinical spectrum: A cross-sectional study. ( 29906544 )
2018
42
Localized bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor treatment. ( 29400293 )
2018
43
Bullous Pemphigoid Associated with Adalimumab Therapy in a Patient with Ulcerative Colitis. ( 29928204 )
2018
44
Modes of Action of Intravenous Immunoglobulin in Bullous Pemphigoid. ( 29793619 )
2018
45
Reflectance confocal microscopy and optical coherence tomography for the diagnosis of bullous pemphigoid and pemphigus and surrounding sub-clinical lesions. ( 29341355 )
2018
46
Detection of I+-defensin in blister fluids as potential biomarkers for bullous pemphigoid patients by matrix-assisted laser desorption ionization/time-of-flight mass spectrometry. ( 29407691 )
2018
47
Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature. ( 29706950 )
2018
48
Light Chain Deposition Disease with Bullous Skin Lesions Mimicking Atypical Bullous Pemphigoid. ( 29135016 )
2018
49
Intravenous immunoglobulin reduces pathogenic autoantibodies, serum IL-6 levels and disease severity in experimental bullous pemphigoid models. ( 29391250 )
2018
50
A case of acquired haemophilia A in a patient with bullous pemphigoid and review of the Japanese literature. ( 29952290 )
2018
Sources

Variations for Bullous Pemphigoid

About this section
Sources

Expression for Bullous Pemphigoid

About this section
Search GEO for disease gene expression data for Bullous Pemphigoid.
Sources

Pathways for Bullous Pemphigoid

About this section

Pathways related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 65
Show member pathways
 13.77 CCL11 CCL17 COL17A1 DSP IL5 ITGA6
2
Integrin Pathway 65
Show member pathways
 13.31 CCL11 CCL17 COL17A1 ITGA6 ITGB4 LAMA3
3
Phospholipase-C Pathway 65
Show member pathways
 12.99 COL17A1 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
4
Focal Adhesion 1 38
Show member pathways
 12.81 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
5
Allograft rejection 1 38
Show member pathways
 12.79 CCL11 HLA-DQB1 HLA-DRB1 IL5 RNASE3 TNFSF13B
6
Pathways in cancer 38
12.76 IL5 ITGA6 LAMA3 LAMB3 LAMC2
7
Beta-Adrenergic Signaling 65
Show member pathways
 12.72 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
8
Collagen chain trimerization 67
Show member pathways
 12.58 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3
9
Degradation of the extracellular matrix 67
Show member pathways
 12.41 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3
10
Keratinization 67
Show member pathways
 12.39 DSG1 DSG3 DSP EVPL PPL
11
MET promotes cell motility 67
Show member pathways
 12.31 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
12
Cell junction organization 67
Show member pathways
 12.18 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3
13
G-protein signaling Regulation of p38 and JNK signaling mediated by G-proteins 23
Show member pathways
 12.07 CCL11 CCL17 COL17A1 ITGA6 ITGB4 LAMA3
14
Toxoplasmosis 38
Show member pathways
 12.07 HLA-DQB1 HLA-DRB1 ITGA6 LAMA3 LAMB3 LAMC2
15
ECM-receptor interaction 38
Show member pathways
 12.01 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
16
Adhesion 4
11.94 DSP ITGA6 ITGB4 PLEC
17
Apoptotic cleavage of cellular proteins 67
Show member pathways
 11.88 DSG1 DSG3 DSP PLEC
18
Cytoskeleton remodeling Neurofilaments 23
Show member pathways
 11.84 DSP DST EVPL PLEC PPL
19
Amoebiasis 38
11.8 LAMA3 LAMB3 LAMC2
20
Hematopoietic cell lineage 38
11.78 HLA-DQB1 HLA-DRB1 IL5 ITGA6
21
Rheumatoid arthritis 38
11.77 HLA-DQB1 HLA-DRB1 TNFSF13B
22
Small cell lung cancer 38
11.75 ITGA6 LAMA3 LAMB3 LAMC2
23
Staphylococcus aureus infection 38
11.6 DSG1 HLA-DQB1 HLA-DRB1
24
IL4-mediated signaling events 1
11.59 CCL11 CCL17 IL5
25
Lung fibrosis 1
11.59 CCL11 DSP IL5
26
Cell adhesion_ECM remodeling 23
11.57 LAMA3 LAMB3 LAMC2
27
Th2 Differentiation Pathway 66
11.42 CCL11 CCL17 IL5
28
a6b1 and a6b4 Integrin signaling 1
11.19 COL17A1 ITGA6 ITGB4
29
G-protein signaling_RhoB regulation pathway 23
11.13 CCL11 CCL17 IL5 TNFSF13B
30
G-protein signaling_Rap2B regulation pathway 23
10.23 CCL11 CCL17 COL17A1 IL5 ITGA6 ITGB4
Sources

GO Terms for Bullous Pemphigoid

About this section

Cellular components related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell junction GO:0030054 9.97 COL17A1 DSG1 DSG3 DSP DST EVPL
2 intermediate filament GO:0005882 9.77 DSP DST EVPL PLEC PPL
3 cornified envelope GO:0001533 9.65 DSG1 DSG3 DSP EVPL PPL
4 basement membrane GO:0005604 9.63 COL17A1 DST ITGA6 LAMA3 LAMB3 LAMC2
5 MHC class II protein complex GO:0042613 9.48 HLA-DQB1 HLA-DRB1
6 laminin-5 complex GO:0005610 9.4 LAMA3 LAMB3
7 desmosome GO:0030057 9.35 DSG1 DSG3 DSP EVPL PPL
8 hemidesmosome GO:0030056 9.02 COL17A1 DST ITGA6 ITGB4 PLEC
9 plasma membrane GO:0005886 10.23 COL17A1 DSG1 DSG3 DSP DST HLA-DQB1
10 extracellular region GO:0005576 10.09 CCL11 CCL17 COL17A1 IL5 LAMA3 LAMB3

Biological processes related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.93 CCL11 CCL17 HLA-DQB1 HLA-DRB1 IL5 TNFSF13B
2 cell adhesion GO:0007155 9.91 CCL11 DSG1 DSG3 DST ITGA6 ITGB4
3 keratinization GO:0031424 9.83 DSG1 DSG3 DSP EVPL PPL
4 cornification GO:0070268 9.8 DSG1 DSG3 DSP EVPL PPL
5 extracellular matrix organization GO:0030198 9.8 COL17A1 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
6 wound healing GO:0042060 9.77 DSP DST EVPL PLEC PPL
7 cell-matrix adhesion GO:0007160 9.73 COL17A1 ITGA6 ITGB4
8 integrin-mediated signaling pathway GO:0007229 9.72 DST ITGA6 ITGB4
9 skin development GO:0043588 9.67 DSP ITGA6 ITGB4
10 epidermis development GO:0008544 9.63 COL17A1 DSP EVPL LAMA3 LAMB3 LAMC2
11 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.57 HLA-DQB1 HLA-DRB1
12 amelogenesis GO:0097186 9.54 ITGA6 ITGB4
13 nail development GO:0035878 9.52 ITGA6 ITGB4
14 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.51 HLA-DQB1 HLA-DRB1
15 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.48 HLA-DQB1 HLA-DRB1
16 intermediate filament cytoskeleton organization GO:0045104 9.35 DSP DST EVPL PLEC PPL
17 hemidesmosome assembly GO:0031581 9.23 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3

Molecular functions related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cadherin binding GO:0045296 9.71 EVPL ITGA6 PLEC PPL
2 structural constituent of cytoskeleton GO:0005200 9.54 DSP PLEC PPL
3 cytokine activity GO:0005125 9.46 CCL11 CCL17 IL5 TNFSF13B
4 insulin-like growth factor I binding GO:0031994 9.32 ITGA6 ITGB4
5 MHC class II receptor activity GO:0032395 9.26 HLA-DQB1 HLA-DRB1
6 structural molecule activity GO:0005198 9.17 DSP DST EVPL LAMA3 LAMB3 PLEC
7 neuregulin binding GO:0038132 8.96 ITGA6 ITGB4
Sources

Sources for Bullous Pemphigoid

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....